TickerStat.comwe like data

Cytokinetics Inc (CYTK)

Price$72.72Cached quote
CYTKNasdaq
Loading local price history

Financial charts

Revenue

Net income

Free cash flow

Total cash / debt

CashTotal debt

Financial statements

28 annual periodsNewest to oldest
2025202420232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998
Revenue$88.0M$18.5M$7.5M$94.6M$70.4M$55.8M$26.9M$31.5M$13.4M$106.4M$28.7M$46.9M$30.6M$7.6M$4.0M$2.6M$81.5M———————————
Research & development$416.0M$339.4M$330.1M$240.8M$159.9M$97.0M$86.1M$89.1M$90.3M$59.9M$46.4M$44.4M$49.5M$35.6M$37.2M$38.0M$39.8M———————————
Operating expenses$700.3M$554.7M$503.7M$418.8M$256.7M$149.8M$125.7M$120.4M$126.8M$87.7M$66.1M$61.7M$64.5M$48.0M$52.0M$52.2M$55.4M———————————
Operating income−$612.3M−$536.2M−$496.2M−$324.2M−$186.3M−$93.9M−$98.9M−$88.9M−$113.4M$18.7M−$37.4M−$14.8M−$33.9M−$40.5M−$48.0M−$49.6M$26.1M———————————
Operating margin−695.44%−2,902.72%−6,589.71%−342.75%−264.54%−168.27%−367.97%−282.26%−848.26%17.56%−130.53%−31.43%−110.59%−535.22%−1,199.10%−1,926.08%32.00%———————————
EBITDA−$602.1M−$526.7M−$484.3M−$318.4M−$184.0M−$92.1M−$97.6M−$87.7M−$111.5M$19.4M−$36.8M−$14.3M−$33.5M−$39.9M−$46.7M−$47.7M$28.1M———————————
EBITDA margin−683.94%−2,851.13%−6,431.78%−336.61%−261.31%−164.99%−363.16%−278.33%−833.90%18.26%−128.47%−30.39%−109.18%−527.40%−1,166.68%−1,852.35%34.48%———————————
Net income−$785.0M−$589.5M−$526.2M−$389.0M−$215.3M−$127.3M−$121.7M−$106.3M−$127.8M$16.5M−$37.5M−$14.6M−$33.7M−$40.4M−$47.9M−$49.3M$24.5M−$56.4M−$48.9M−$57.1M−$42.3M−$37.2M−$32.7M−$23.1M−$15.9M−$13.1M−$7.3M−$2.0M
Net profit margin−891.60%−3,191.11%−6,988.63%−411.21%−305.72%−228.00%−452.93%−337.41%−955.94%15.46%−130.86%−31.20%−110.01%−534.07%−1,196.50%−1,912.57%30.10%———————————
Basic EPSper basic share-$6.54-$5.26-$5.45-$4.33-$2.80-$1.97-$2.11-$1.95-$2.59$0.41-$0.97-$0.41-$1.24-$2.30-$25.82-$27.61$15.42———————————
Diluted EPSper diluted share-$6.54-$5.26-$5.45-$4.33-$2.80-$1.97-$2.11-$1.95-$2.59$0.39-$0.97-$0.41-$1.24-$2.30-$25.82-$27.61$15.06———————————
Review official source filings ↗

Owners

Reported shareholders

Reference date Jun 30, 2026

Reported holdings Number of shares

View holders
Top 20 reported holders of CYTK
HolderShares held
BlackRock, Inc.
20.09M
T. Rowe Price Investment Management, Inc.
18.72M
WELLINGTON MANAGEMENT GROUP LLP
6.93M
VANGUARD PORTFOLIO MANAGEMENT LLC
6.71M
STATE STREET CORP
6.49M
VANGUARD CAPITAL MANAGEMENT LLC
6.12M
FMR LLC
5.03M
Avoro Capital Advisors LLC
5M
BANK OF AMERICA CORP /DE/
4.64M
GEODE CAPITAL MANAGEMENT, LLC
3.71M
RTW INVESTMENTS, LP
2.86M
Polar Capital Holdings Plc
2.25M
PRICE T ROWE ASSOCIATES INC /MD/
1.96M
GOLDMAN SACHS GROUP INC
1.76M
Capital Research Global Investors
1.69M
NORTHERN TRUST CORP
1.65M
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC
1.6M
Integral Health Asset Management, LLC
1.6M
JPMORGAN CHASE & CO
1.59M
Point72 Asset Management, L.P.
1.59M

Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.

Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data

Insider buys & sells

Jul 1, 2024–Jun 30, 2026
Buys0$0.00 disclosed value
Sells (SEC code S)169$61.35M disclosed value
169 recent transactions
TransactionInsiderTypeSharesPriceValueOwned after
Jun 29, 2026Form 4 · 10b5-1Lee SungEVP, Chief Financial OfficerSellCommon Stock3.1K$85.00$266.4K63.2K
Jun 24, 2026Form 4 · 10b5-1Lee SungEVP, Chief Financial OfficerSellCommon Stock38.7K$82.30$3.19M63.2K
Jun 23, 2026Form 4 · 10b5-1Malik Fady IbrahamEVP Research & DevelopmentSellCommon Stock3.5K$79.51$278.3K153.9K
Jun 15, 2026Form 4 · 10b5-1Blum Robert IPresident & CEOSellCommon Stock7.5K$70.46$528.5K385.3K
Jun 9, 2026Form 4 · 10b5-1Malik Fady IbrahamEVP Research & DevelopmentSellCommon Stock3.5K$67.98$237.9K153.9K
Review ownership filings at SEC.gov ↗

Community posts

View community

It’s quiet here.

No posts about CYTK yet. Start the conversation.

Write the first post